Cabozantinib

證據等級: L5

預測適應症: 10 個

Cabozantinib: Drug Repurposing Candidate — Pending TxGNN Evaluation

One-Sentence Summary

Cabozantinib (DB08875) is a small-molecule kinase inhibitor with established antineoplastic activity, currently not marketed in Taiwan and with no authorized indications on record in this Evidence Pack. The TxGNN predicted indications field is empty in the current Evidence Pack, meaning no repurposing target has been generated yet. This report cannot render a complete repurposing evaluation until the missing data — particularly TxGNN predictions, original indication records, and MOA details — are supplied.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	Not available — `predicted_indications` array is empty
TxGNN Prediction Score	Not available
Evidence Level	L5 — model prediction not yet generated
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Cytotoxicity

Cabozantinib is a well-characterized multi-kinase inhibitor (VEGFR2, MET, RET, AXL) used clinically in oncology, meeting the antineoplastic criterion by drug class. Although the current Evidence Pack does not carry DrugBank category tags or confirmed MOA text, the drug name and DrugBank ID (DB08875) unambiguously identify it as a targeted antineoplastic agent.

Item	Content
Cytotoxicity Classification	Targeted therapy — multi-kinase inhibitor (not conventional cytotoxic)
Myelosuppression Risk	Low to moderate (targeted agents carry lower haematologic toxicity than conventional cytotoxics; confirm with package insert)
Emetogenicity Classification	Low
Monitoring Items	CBC with differential, liver function (AST/ALT), renal function, thyroid function, blood pressure, urine protein
Handling Protection	Standard targeted-agent precautions; confirm cytotoxic handling requirements against institutional protocol and approved labelling

Full toxicity details (myelosuppression incidence, specific thresholds) are not available in this Evidence Pack. Please refer to the approved package insert warnings and precautions.

Safety Considerations

Please refer to the package insert for safety information.

Key warnings, contraindications, and drug-drug interaction data are all absent from this Evidence Pack (Data Gap DG001). The DDI query returned zero results and no TFDA labelling text has been parsed. No safety data can be reported here without risking inaccuracy.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete — the predicted_indications array is empty and two blocking/high-severity data gaps (DG001: TFDA label text; DG002: MOA) remain unresolved. There is no repurposing target to evaluate, and no safety signal summary is available for risk assessment.

To proceed, the following is needed:

TxGNN predictions — re-run the TxGNN pipeline for DB08875 and populate predicted_indications with at least one candidate disease
Original indication data — retrieve approved indication text from TFDA package insert (remediation: download and parse TFDA PDF)
Mechanism of action (MOA) — query DrugBank API for DB08875 pharmacodynamics and target profile (remediation per DG002)
Safety label text — parse TFDA 仿單 for key warnings and contraindications (remediation per DG001)
DDI data — re-query DDI database; current result is not_found with zero interactions, which may reflect a query failure rather than a true absence of interactions
Regulatory cross-check — although Taiwan shows 0 licenses, Cabozantinib holds approvals in other jurisdictions (EMA, FDA); a cross-jurisdictional lookup would enrich the regulatory context
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.